Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.30 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4984038 | 0.81 | KDM4E (0.32) | KMT2AKDM4E | |
| SCHEMBL4985780 | 0.77 | POLB (0.30) | — | |
| SCHEMBL4985752 | 0.77 | KDM4E (0.35) | ALDH1A1RAB9AKDM4E | |
| SCHEMBL4985385 | 0.76 | ALDH1A1 (0.33) | MEN1NPC1ALDH1A1TP53RAB9A | |
| SCHEMBL17529621 | 0.70 | PDE10A (0.32) | TXNRD1TAAR1 | |
| SCHEMBL315179 | 0.70 | POLB (0.33) | KMT2AKDM4E | |
| SCHEMBL491627 | 0.70 | — | — | |
| SCHEMBL491297 | 0.68 | — | — | |
| SCHEMBL1636152 | 0.68 | — | — | |
| SCHEMBL18300146 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7414066-B2 | Amide compounds and medications containing the same technical field | KOWA COMPANY LTD. (JP) | 2008-08-19 | — | — | US | disclosed |
| US-7393866-B2 | Amide compounds and medications containing the same | KOWA COMPANY, LTD. (JP) | 2008-07-01 | — | — | US | disclosed |
| EP-0979823-B1 | NOVEL AMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | KOWA CO (JP) | 2006-03-29 | — | — | EP | disclosed |
| US-20050131001-A1 | Novel amide compounds and medications containing the same technical field | KOWA COMPANY LTD. (JP) | 2005-06-16 | — | — | US | disclosed |
| US-20050131002-A1 | Novel amide compounds and medications containing the same | KOWA COMPANY LTD. (JP) | 2005-06-16 | — | — | US | disclosed |
| US-6849647-B1 | Amide compounds and medications containing the same technical field | KOWA COMPANY, LTD. (JP) | 2005-02-01 | — | — | US | disclosed |
| EP-0979823-A1 | NOVEL AMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | Kowa Company Ltd. (JP) | 2000-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131001-A1 | Novel amide compounds and medications containing the same technical field | ACAT2, SULT2A1, ACAT1 | MEN1 4353/4885NPC1 472/4885ALDH1A1 1256/4885 |
| US-20050131002-A1 | Novel amide compounds and medications containing the same | ACAT2, SULT2A1, ACAT1 | MEN1 4488/4885NPC1 476/4885ALDH1A1 1410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.